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Clinical trials are paramount for the devel-
opment of medical science and advance-
ment in therapeutics. Mankind has made
great strides in medical science, thanks
to the ever curious scientific acumen of
researchers. But since clinical trials involve
human “participants,” their safety, and
policies to protect their rights justly take
precedence over scientific advancement.
In India, the regulatory agency over-
seeing and approving clinical trials is the
CDSCO, “Central Drugs Standard Control
Organization” (Central Drugs Standard
Control Organization, 2014). The CDSCO
considers and approves only those trials
that have been approved by the Ethics
Committees, thereby, making the Ethics
Committees (EC) the most important link
in safeguarding participant’s rights and
safety. Similarly, even in the USA, the
FDA (Food and Drug Administration) and
the Department of Health and Human
Services have given such powers to the ECs
to protect subject rights.
Unfortunately, there have been many
instances of unethical trials being con-
ducted in India and globally (SOMO,
2008). One such example is the cervical
cancer screening clinical trial conducted
in India and sponsored by US National
Cancer Institute (NCI) and the Bill and
Melinda Gates Foundation. In this trial,
two groups of women were offered cervi-
cal cancer screening while the third group
were not, citing the reason that, in India as
a standard of care cervical cancer screen-
ing is not routinely undertaken. In the
group that was not offered screening, there
were 250 deaths due to cervical cancer.
The ethics committee failed to identify
the issue of withholding the “standard of
care” and an inadequate written informed
consent process (Srinivasan, 2014; Suba,
2014). Another such example is that of
approval of a trial for a fake and dangerous
drug by the ECs in the USA (Kutz, 2009;
Mundy, 2009).
Recently, the CDSCO has made it
mandatory for all the ECs to get reg-
istered and also laid down the require-
ments for registration and functioning
of ECs (Suvarnapathaki, 2013). This has
ushered in the much needed account-
ability required for proper functioning
of the ECs. It has also stipulated that
the Independent ECs can review only
Bioavailability and Bioequivalence stud-
ies and not clinical trials which can be
approved only by the Institutional ECs
(ethics committees attached to hospitals)
(Suvarnapathaki, 2013). But is this enough
to safeguard participant rights? What
about the other shortcomings like, inad-
equate training of members in bioethics,
lack of regular monitoring of the clinical
trials, non-disclosure of conflict of interest
by the EC members and so on.
Studies have shown that the aware-
ness and knowledge of EC members
regarding various important bioethics
concepts is sub-optimal (Brahme and
Mehendale, 2009; Pandiya, 2011; Kadam
and Karandikar, 2012; Nadig et al., 2014).
This is true despite the fact that most
of the members were quite senior and
had ample clinical and research experience
(Brahme and Mehendale, 2009). To obvi-
ate this, accreditation of ECs with organi-
zations like SIDCER Recognition Program
and the Accreditation of Human Research
Protection Program (AAHRP), ICMR
(Indian Council of Medical Research)
and FERCI (Forum for Ethics Committee
Review in India) is recommended (Kadam
and Karandikar, 2012). Also, another
important step would be introducing a
mandatory ethics checklist and a scor-
ing system, for example, from 1 to 5
(1—adequately addressed to 5—grossly
neglected). The ethical concerns that could
be incorporated in such a list could
include—scientific rationale of the study,
equitable and fair selection of subjects,
favorable risk benefit ratio, the informed
consent process, factors likely to affect
the voluntariness, post-trial access, sub-
ject insurance and compensation, financial
inducement, vulnerable population and so
on (Pandiya, 2011; Taylor, 2007). This will
ensure adequate consideration of all eth-
ical concerns and the scoring system will
ensure an objective decision making as
against the current system of voting where
the majority decides the fate of a trial.
Reviewing a trial protocol and award-
ing approval doesn’t end the task of the
EC. Just as the investigator has to provide
regular study updates to the EC, the EC
should also take initiative in regular on-
site monitoring of ongoing clinical trials
to affirm the approval granted on a peri-
odic basis (A Bill further to amend the
Drugs and Cosmetics Act, 1940). This is
something, although mandatory by law, is
lacking (Gogtay et al., 2011; Thomas, 2011;
Nadig et al., 2014; Shetty et al., 2014). The
recent amendment (2013) in the Drugs
and Cosmetics act of 1940 has made it
mandatory for the ECs to submit periodic
reports of ongoing trials to the CDSCObut
to what extent this has been implemented
remains doubtful (A Bill further to amend
the Drugs and Cosmetics Act, 1940).
Another concern that needs to be
addressed is the non-disclosure of conflict
of interest by the EC members and the
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so called, “private hospital-investigator-
EC” nexus (Fleck, 2004; Pandiya, 2011;
Kadam and Karandikar, 2012; Pereira,
2013). To obviate this it has recently
been made mandatory to include at least
50% of government sites for clinical tri-
als (Suvarnapathaki, 2013). Even the law
doesn’t make it mandatory for the EC
members to declare conflict of interest
and hence it is seldom done. We have
come a long way in regulating clinical trials
and improving the functioning of ECs but
there still exist gaps that need to be filled.
To summarize,
• There’s a need to train EC members in
bioethics.
• Mandate accreditation of ECs and a
check list based scoring system to review
protocols to ensure a comprehensive
and fair review wherein all the relevant
scientific and ethical issues have been
adequately addressed.
• Mandatory regular on-site monitoring
and submission of periodic reports.
• Legal liability to declare conflict of inter-
est by the EC members.
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